Janney Montgomery Scott LLC Decreases Stake in Zoetis Inc. $ZTS

Key Points

• Janney Montgomery Scott LLC reduced its stake in Zoetis Inc. by 14.2% during the second quarter, owning 151,342 shares valued at $23.6 million.
• Institutional investors control 92.80% of Zoetis stock, with notable transactions including Nuveen LLC investing over $616 million in the first quarter.
• Zoetis recently reported earnings of $1.76 per share, exceeding estimates, with revenue of $2.46 billion for the quarter, up 4.2% year-over-year.

Janney Montgomery Scott LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 14.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 151,342 shares of the company's stock after selling 24,965 shares during the period. Janney Montgomery Scott LLC's holdings in Zoetis were worth $23,602,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ZTS. Nuveen LLC purchased a new position in Zoetis during the first quarter worth about $616,375,000. Mackenzie Financial Corp raised its stake in Zoetis by 4,158.3% during the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock worth $300,481,000 after purchasing an additional 1,782,110 shares during the period. Sarasin & Partners LLP purchased a new position in Zoetis during the first quarter worth about $255,842,000. Polen Capital Management LLC raised its stake in Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Finally, Amundi raised its stake in Zoetis by 30.8% during the first quarter. Amundi now owns 3,595,628 shares of the company's stock worth $575,691,000 after purchasing an additional 846,909 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.4%

Shares of ZTS stock opened at $146.87 on Thursday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a market capitalization of $65.09 billion, a P/E ratio of 25.28, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90. The company has a 50 day moving average price of $150.02 and a 200 day moving average price of $155.39. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $196.55.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Argus reiterated a "buy" rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price target for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Zoetis currently has an average rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.